ALNYLAM PHARMACEUTICALS, INC. ($ALNY)
Filing Information
| Accession Number | 0001735276-26-000053 |
|---|---|
| Form Type | 4 |
| Filing Date | Mar 5, 2026 |
| Document | View SEC Filing |
Transactions
12
Total Shares
17,455
Total Value
$722,800.78
P&L
+inf% (+$4,760,280.33)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Grant/Award | 4,769 | $0.00 | $0.00 | 66,479 | Direct | โ | View Details | |
EVP, Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 65 | $323.62 | $21,035.30 | 66,414 | Direct | โ | View Details | |
EVP, Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 124 | $324.65 | $40,256.60 | 66,290 | Direct | โ | View Details | |
EVP, Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 356 | $325.63 | $115,924.28 | 65,934 | Direct | โ | View Details | |
EVP, Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 541 | $326.81 | $176,804.21 | 65,393 | Direct | โ | View Details | |
EVP, Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 454 | $327.67 | $148,762.18 | 64,939 | Direct | โ | View Details | |
EVP, Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 138 | $328.71 | $45,361.98 | 64,801 | Direct | โ | View Details | |
EVP, Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 234 | $329.71 | $77,152.14 | 64,567 | Direct | โ | View Details | |
EVP, Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 112 | $330.85 | $37,055.20 | 64,455 | Direct | โ | View Details | |
EVP, Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 129 | $331.93 | $42,818.97 | 64,326 | Direct | โ | View Details | |
EVP, Chief Financial Officer | Common Stock | โ | Mar 2, 2026 | Sale | 53 | $332.64 | $17,629.92 | 64,273 | Direct | โ | View Details | |
EVP, Chief Financial Officer | Stock Option (right to buy) | Derivative | Mar 2, 2026 | Grant/Award | 10,480 | $0.00 | $0.00 | 10,480 | Direct | โ | View Details |